AstraZeneca Imfinzi-Amgen Combo Boosts Survival in Small Cell Lung Cancer

AstraZeneca reported that Imfinzi plus Amgen's Imdelltra improved overall survival in advanced small cell lung cancer in a Phase 3 trial, versus Imfinzi alone. The combination also improved progression-free survival and response rate with no new safety signals. This could shift treatment standards and boost both companies' oncology portfolios, though full data and regulatory review are pending.